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Summary Technologies associated with cardiac resynchronization therapy (CRT) devices and
lead systems have progressed. However, dislocation after coronary sinus (CS) lead placement
continues to be a problem. Furthermore, CS lead positioning at the site of the ventricular latest
activation (detected by echocardiography) is often problematic due to large vessel size leading
to the lead placement (wedge site) near the apical site. The newly available active ﬁxation
CS lead (StarFix 4195) enabled us to anchor the CS lead at the target site regardless of vessel
size and availability of a wedge site. We report on seven patients who had previously faileddislocation conventional CS lead positioning due to large vessel size and a low phrenic nerve stimulation
threshold at the optimal site and lack of stabilization followed by dislocation at the target
vein. We attempted to replace the original lead with the StarFix 4195. All patients successfully
underwent StarFix 4195 lead replacement at the target site and responded to CRT in the long-
term follow-up period.
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he newly available active ﬁxation coronary sinus (CS) lead
StarFix 4195TM, Medtronic Inc., Minneapolis, MN, USA) is a
nipolar, steroid eluting, over the wire left ventricular (LV)
Published by Elsevier Ireland Ltd. All rights reserved.
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Table 1 Details of seven patients who underwent StarFix 4195 lead replacement.
Patient Age Sex NYHA class Diagnosis Cause of StarFix use Effect of CRT
1 69 M III CHF after DDD pacing Dislocation of Attain 4194 Responder
2 80 M III—IV DCM Dislocation of Attain 4193 Responder
3 36 M III Corrected TGA PN stimulation at the optimal site Responder
4 78 M III—IV CHF after DDD pacing PN stimulation at the optimal site Responder
5 72 M III OMI PN stimulation at the optimal site Responder
6 71 M III DCM Dislocation of Attain 4194 Responder
7 77 F III—IV Cardiac sarcoidosis Dislocation of Attain 4194 Responder
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tCHF, congestive heart failure; CRT, cardiac resynchronization thera
OMI, old myocardial infarction; PN, phrenic nerve; TGA, transposi
pacing lead characterized by three deployable lobes which
can be deployed by advancing the outer pushing tube of
the proximal catheter. The StarFix 4195 lead has enabled
us to anchor the CS lead at the target site regardless of
vessel size and availability of a wedge site, and decreased
the rate of lead dislocation which might be followed by LV
capture threshold rise and/or appearance of phrenic nerve
stimulation. We report the ﬁrst experience of cardiac resyn-
chronization therapy (CRT) using the StarFix 4195 CS lead
system in Japan.
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Figure 1 Representative case. (A) Coronary venography (right ante
target lateral vein, which was relatively straight and lacked vessel bra
vessel. Of note, the posterior vein was not suitable for coronary sinu
distance between the CS and the right ventricular lead tips, possib
therapy. (B) Final CS lead position (Medtronic Attain 4194) in the la
operation. Note the tip of CS lead was wedged at a more apical port
catheter was removed. (D) During the second operation, the StarFix 4
of the lateral coronary vein. (E) The CS lead maintained a stable
between the indicator rings is reduced indicating that all the three l
acceptable.CM, dilated cardiomyopathy; NYHA, New York Heart Association;
of the great arteries.
ase report
rom November, 2007 through March, 2009, seven patients
six males and one female; median age 69 years; range
6—80 years) experienced failure of CS lead placement and
herefore underwent active ﬁxation within the target coro-
ary vein using the StarFix 4195 lead. All patients had
everely decreased LV ejection fraction (<35%) and were
n New York Heart Association functional class III or IV
espite optimal drug therapy. Etiologies of heart failure in
rior oblique view) of patient 1 (upgrade from DDD) showing the
nches of appropriate size for wedging at the mid-portion of the
s (CS) lead placement because that resulted in an insufﬁcient
ly leading to unfavorable effects of cardiac resynchronization
teral vein with guidewire protruding at the time of the initial
ion. (C) The Attain 4194 lead dislocated soon after the guiding
195 CS lead was used for active ﬁxation within the mid-portion
position after the guiding catheter was removed. The space
obes were deployed. Pacing and sensing performance were all
e178 T. Nagai et al.
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Cigure 2 Changes in left ventricular end-systolic volume (LVES
iﬁcantly improved during long-term follow-up after cardiac res
rom baseline to follow-up were compared using Student’s pair
he seven patients are shown in Table 1. CRT pacemakers
r CRT deﬁbrillators were implanted with standard tech-
iques using an endovascular approach via a left axillary
ein. Target coronary vein branch for the optimal CS lead
ositioning (according to ﬁndings of echocardiography) was
etermined after CS venogram. The conventional CS lead
ystems (Attain 4193 and 4194) were used for LV pacing
n all patients. We used the StarFix 4195 only in patients
ho had failed conventional CS lead positioning due to lack
f ‘‘wedge position’’ because of large vessel size, a low
hrenic nerve stimulation threshold at the optimal site, and
islocation at the target vein even after successfully posi-
ioned at the ‘‘wedge position’’. Because the StarFix 4195
ead had not been approved for clinical use in Japan (before
pril 2009), the medical ethics committee at Ehime Uni-
ersity Hospital approved the individual import and usage
f the lead. All patients gave written informed consent.
ll patients were followed up and echocardiographic data
ere obtained every 3 months. CRT responder status was
eﬁned by a decrease in LV end-systolic volume of ≥15%
sing the modiﬁed biplane Simpson’s method at follow-up
chocardiography.
Clinical data for the seven patients are shown in Table 1.
he StarFix 4195 was used because of a low phrenic nerve
timulation threshold at the ‘‘wedge position’’ in three
atients, and a lack of stabilization followed by disloca-
ion when the tip of the pacing lead was inserted at the
‘wedge position’’ in four patients. All patients successfully
nderwent StarFix 4195 lead replacement at the target vein
fully deployed within lateral or posterolateral branch of
he coronary vein) without complications. The parameters
or sensing (R wave of 11± 7mV) and pacing (threshold at
.4ms pulse width of 1.4± 1.3 V) were all acceptable. A
epresentative case is shown in Fig. 1. After a follow-up
eriod of 12± 6 months, none of the leads have dislodged.
esults have been completely satisfactory, with adequate
ensing and pacing function. As compared with baseline,
V ejection fraction and LV end-systolic volume improved
a
l
t
t
dd left ventricular ejection fraction (LVEF). Both parameters sig-
ronization therapy. The changes in echocardiographic variables
test. A level of statistical signiﬁcance was set as p < 0.05.
igniﬁcantly after long-term follow-up (Fig. 2). All patients
ere considered responders to CRT by echocardiography.
hus, the StarFix 4195 is a useful device for reducing
he frequency of CS lead failure during and after CRT
evice implantation and thereby maximizing the efﬁcacy
f CRT.
iscussion
RT is widely recognized as a treatment for chronic heart
ailure in patients with severely impaired LV systolic func-
ion combined with dyssynchrony [1,2]. Although the most
elayed electromechanical activation site should be paced
o maximize the effect of CRT [3—6], standard transvenous
S lead placement at the site of the ventricular latest acti-
ation (detected by echocardiography) is often challenging
ecause of anatomic conditions such as a lack of adequate
ranches of coronary veins, low phrenic nerve stimulation
hresholds, and high LV capture thresholds. Even when such
roblems are not encountered, CS lead stabilization at the
ptimal site can become impossible if a ‘‘wedge position’’
s not available due to large vessel size. Furthermore, dislo-
ation after successful CS lead placement at the target vein
emains an issue.
CS lead dislocation occurs in 8—11% of patients who
ndergo CRT device implantation without active ﬁxation
f the CS lead [7] and it is one of the critical problems
ffecting patients who undergo CRT device implantation.
islocation is associated with LV capture loss and phrenic
erve stimulation, which might result in repositioning of
he CS lead after the initial procedure. In order to avoid
S lead dislocation, the pacing lead should be inserted
t the ‘‘wedge position’’. However, that position is often
ocated near the apical site, resulting in a decreased dis-
ance from the right ventricular pacing lead positioned at
he apex. This may lead to a decrease in the CRT respon-
er rate [8]. Even when the CS lead is positioned at the
[10] Hansky B, Vogt J, Gueldner H, Schulte-Eistrup S, Lamp B,New CS lead for CRT
‘‘wedge position’’, dislocation of the lead can still occur.
Previous reports have suggested the usefulness of other CS
lead stabilization techniques such as stenting [9] or active
ﬁxation using a screw-in lead [10]. However, CS lead place-
ment using the StarFix 4195 lead is safer than the other
methods in terms of a reduced risk of perforation and insu-
lation defects of the pacing lead. A major limitation of the
StarFix 4195 lead placement is extractability after long-
term implantation, particularly in cases of lead infection.
Because there are no published data regarding any type of
CS lead extraction, additional studies in a larger patient
population are needed. Nonetheless, taking the poor prog-
nosis of drug refractory heart failure into consideration, we
think the CS lead positioning at the optimal site is a ﬁrst
priority.
Conclusion
Despite limited data, our results indicate that the newly
available StarFix 4195 CS lead reduces the frequency of lead
dislocation and maximizes the efﬁcacy of CRT.
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